New vaccines invented by Weill Cornell Medicine College (USA) may help reverse bowel cancer, including colon cancer and rectal cancer.
The team of scientists led by geneticist Steven Lipkin, from Weill Cornell Medicine College (USA), said their bowel cancer vaccine has passed animal tests and has promising evidence. will achieve similar success in humans.
The new vaccine targets Lynch Syndrome , a genetic problem that puts people with it at a very high risk of developing bowel cancer (also known as colorectal cancer, including colon cancer and colon cancer). colon). Statistics in the US show that up to 1.17 million people suffer from this genetic problem and are 70-80% higher at risk of bowel cancer than the rest of the population.
Lynch syndrome causes a mutation that prevents the DNA of the sufferer from repairing itself, which leads to cancer , a disease that has been shown to be closely related to DNA defects.
According to Mr. Lipkin, his vaccine and his colleagues aimed at this mutation. In animal testing, when the vaccine is used in conjunction with a common anti-inflammatory drug, it may help mice with Lynch syndrome to drastically reduce the risk of developing cancer and if there is cancer, the likelihood longer life expectancy is also higher. It is estimated that they live up to 60% longer than those that are not vaccinated and have a lifespan equivalent to those without Lynch syndrome.
The team of scientists is continuing the research process to advance clinical trials on humans and further to bring this vaccine to market.